Meta Pharmaceuticals Smashes Records with Highest Quarterly Performance Ever in Q3
Meta Pharmaceuticals Achieves Record-Breaking Quarterly Performance
Meta Pharmaceuticals announced on the 28th that it recorded sales of 9.4 billion won and operating profit of 2.1 billion won in the third quarter of this year. This is the highest quarterly performance ever since its founding, an increase of 112% and 251%, respectively, compared to the same period last year.
An official from Meta Pharmaceuticals said, “We will be developing our own research and development medical devices and hair loss devices, such as the dental implant ‘Plan Implant’ released in the first half of 2024, the polydioxanone (PDO) thread ‘Minting’ for lifting procedures, and the hair transplant device ‘Meta Transplanter’. “We recorded good performance as we began expanding our business to supply prescription drugs such as treatments ‘Momod’ and ‘Momota’,” he explained.
Meta Pharmaceuticals plans to focus on upgrading its business structure and strengthening its global capabilities in the fourth quarter. The hair transplant medical device, which has the highest market share in Korea, will be introduced at the ‘2024 ISHRS (International Society for Hair Transplantation)’ held in Denver, Colorado, USA.
Through this, we plan to strengthen our global network in North and Central America, Europe, and Southeast Asia, including Turkey, which is rapidly emerging as the world’s center of hair transplantation. This year, we aim to achieve annual sales of 33 billion won and operating profit of 6 billion won.
Lee Soo-jin, CEO of Meta Pharmaceuticals, said, “We are finalizing investment and mergers and acquisitions (M&A) in a dental medical device manufacturing company,” and added, “We expect a dramatic increase in performance next year when a nationwide network centered on large specialty hospitals is completed.”
Meta Pharmaceuticals is committed to innovation and growth, and its recent quarterly performance is a testament to its success. With its focus on research and development, global expansion, and strategic partnerships, the company is poised for continued growth and success in the medical device industry.